Acrivon Therapeutics, Inc.·4

Jan 16, 4:45 PM ET

Cuillerot Jean-Marie 4

4 · Acrivon Therapeutics, Inc. · Filed Jan 16, 2024

Insider Transaction Report

Form 4
Period: 2024-01-11
Cuillerot Jean-Marie
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2024-01-11+99,30099,300 total
    Exercise: $4.82Exp: 2034-01-10Common Stock (99,300 underlying)
Footnotes (1)
  • [F1]Twenty-five percent (25%) of the shares subject to the option shall vest on February 1, 2025, and the remaining shares subject to the option shall vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Documents

1 file
  • 4
    form4.xmlPrimary